When classified by pituitary tumor subtype, 11 (1.77%) of the 621 patients with nonfunctional pituitary tumors, 10 (6.06%) of the 155 patients with growth hormone-type pituitary tumors, 1 (2.38%) of the 42 patients with corticotropic hormone-type pituitary tumors, and 2 (5.88%) of the 34 patients with prolactin-type pituitary tumors experienced delayed epistaxis. This evidence concerns the gene GH1 and pituitary tumor.